Kornimate/medical-research-clean huggingface dataset:
benefits of ballistic tests after the anterior cruciate ligament surgery

Conditions: Anterior Cruciate Ligament Injuries; Anterior Cruciate Ligament Rupture

Summary: during physical activities, the time available to produce a force is infinitely shorter than the time required to reach maximal muscle capacity. previous studies have observed that the time elapsed between ground contact and acl rupture is on average 50-60 ms, suggesting that this is the time window available for any attempt at dynamic stabilization of the joint through muscle contraction. sports movements include ballistic movements, defined as very fast movements whose objective is to accelerate a moving mass as much as possible so that it reaches a high speed in a very short time. this is the case for vertical jumps, running and most movements performed in physical and sporting activities. thus; (1) isokinetic tests do not allow a rigorous analysis of the components related to the speed of the movement; (2) functional tests such as jumping, which only give a distance between one leg and the other, do not allow the calculation of precise and reproducible variables concerning the force and speed of the movement, in particular during the first milliseconds of the movement, and do not provide information on compensation phenomena. it is therefore interesting to use the ballistic tests developed to monitor the movements of athletes as a new possible indicator of the return to sport. the main objective of this study is to evaluate the performance of ballistic tests in predicting failure to return to physical activity 24 months after acl surgery.


Eligibility criteria:
inclusion criteria: * adult patient (\> 18 years), * patient who has undergone acl reconstruction of the hamstrings with or without associated extra-articular plastic surgery: * isolated acl sprain without injury to the collateral ligaments or the pcl, * acl reconstruction without associated meniscal injury or with repaired or menisctomized meniscal injury, * having to perform a k-starts test and an isokinetic test, * having the tegner score before the rupture. exclusion criteria: * patient with high cardio-respiratory risk, * osteoarticular and neuromuscular traumatic sequelae of the lower limbs, * degenerative neuromuscular diseases, * connective tissue and collagen disease (e.g. marfan), * follow-up of a medical treatment that may influence the neuro-muscular system (e.g., antidepressants, etc.) during the tests, * pregnant, parturient or breastfeeding patient.
prochlorperazine vs metoclopramide

Conditions: Migraine

Summary: migraine headaches are a common reason for patients to present to an emergency department. we are comparing two different medications to see which one is better for patients who present ot an emergency room with a migraine headache.

one-third of the five million headache patients who present to us emergency departments (ed) annually have a migraine headache. the anti-emetic dopamine receptor antagonists have proven efficacy for migraines, are at least as well-tolerated as triptans, and enjoy wide-spread use in north american eds. however, it is not yet clear which medication within this class and which dosage is optimal. therefore, we propose a randomized clinical trial to compare the efficacy and tolerability of two standard medications for migraine. specific aim: to compare the efficacy of metoclopramide versus prochlorperazine for the emergency department treatment of migraine headaches. both of these medications will be combined with diphenhydramine to prevent extra-pyramidal side effects. patients will be enrolled as participants if they present to one of the participating eds and consent to participate. medications will be administered as an intravenous drip over 15 minutes. rescue medication will be administered, if needed, after one hour. a follow-up phone call will be conducted 24 hours after the ed visit.

Eligibility criteria:
inclusion criteria: * present to the ed with an acute migraine headache exclusion criteria: * secondary headache * if the patient is to receive a lumbar puncture in the ed * maximum temperature greater than 100.3 degrees * new objective neurologic abnormality at the time of physical exam * allergy or intolerance to a study medication * pregnancy * previous enrollment

Keywords: migraine headache
microarray analysis of gene expression and identification of progenitor cells in lung carcinoma

Conditions: Carcinoma, Giant Cell; Carcinoma, Non-Small-Cell Lung; Lung Cancer

Summary: this study will help us understand the gene expression profiles of lung cancer. we will identify genes related to lung cancer development, their growth and metastasis to the lung. in addition, we will examine the role nicotine in the development and progression of lung tumors of smokers, ex-smokers, non-smokers on supplemental nicotine and non smokers with no exposure to nicotine.


Eligibility criteria:
inclusion criteria:adults with non small cell lung cancer exclusion criteria:na
study of peripheral arterial calcification

Conditions: PAD

Summary: aim of the work : 1. using different calcification scoring systems to investigate the association between arterial calcification and clinical outcome following endovascular therapy

peripheral arterial disease (pad) is a worldwide health problem and its prevalence is increasing among aging population. symptomatic pad is a major cause of major amputation with reduction of the functional capacity and quality of life . arterial calcification is calcium crystallization deposits in the extracellular matrix of the intima and media . medial calcification is usually associated with chronic kidney disease and diabetes mellitus, while intimal calcification comes usually as a part of atherosclerotic process . the relationship between calcification and pad is well established . arterial calcification is associated with increased risk of procedural failure and major amputation . many calcium scoring systems have been proposed, including peripheral arterial calcium scoring scale (pacss which highlights the pathologic location of calcification along with the length of the segment affected. the peripheral academic research consortium (parc) suggested another calcium scoring scale that classified calcification into 4 major grades . the defenetive ca++ have proposed another calcium severity scoring . intravascular ultrasound (ivus) is highly sensitive to presence and location of atherosclerotic calcium . the impact of intimal and medial vascular calcification on the safety and effectiveness of endovascular devices to treat symptomatic peripheral arterial disease (pad) remains poorly defined warranting continued research to elaborate relationship between calcification and endovascular outcome.

Eligibility criteria:
inclusion criteria: 1. patients with peripheral arterial disease 2. patients with disabling limb claudication 3. patients with rest pain 4. patients with minor tissue loss 5. patients admitted to vascular surgery department for endovascular intervention of a denovo lower limb arterial lesion exclusion criteria: * 1)patient's age less than 50. 2)patients with major tissue loss \[ rutherford category 6\] 3)patients with recurrent lesion after previous intervention. 4)patients with double level arterial lesion. 5) patients refusing to participate in this study
vital - vap prevention by bip (bactiguard infection protection) ett evac in belgian icus

Conditions: Ventilator-associated Pneumonia

Summary: the study objective is to determine vap (ventilator associated pneumonia) baseline incidence in the icu in patients receiving endotracheal tubes with evacuation lumen with and without bactiguard coating. the study is randomized, prospective, controlled and blinded. all adult patients hospitalized in the icus from two tertiary hospitals (i.e.: centre hospitalier universitaire sart tilman liège , centre hospitalier chrétien de liège) and considered to be ventilated for more than 24 hours will be eligible to participate in the study.

the aim of the study is to determine vap (ventilator associated pneumonia) baseline incidence in the icu in patients receiving endotracheal tubes with evacuation lumen with and without bactiguard infection protection (bip) coating. vap is likely to occur in 10-20% of patients who are ventilated for at least 48 hours. these patients face a mortality risk estimated to be twice as high compared with similar icu patients without vap. furthermore, vap results in an average excess length of icu stay with high hospital cost. bactiguard has developed an endotracheal tube coated with a thin layer of non-releasing metals (gold, silver and palladium) firmly attached to the surface. this bactiguard coating is tissue friendly and aims to achieve an optimal combination of anti-infective properties to reduce biofilm formation, colonization and subsequent respiratory infection. bactiguard coated urinary products have been on market since 1995 (initially in us, then also in japan \& europe) and used in a large number of clinical studies and evaluations, showing reduction of urinary tract infections and also antibiotics use. a bip ett (without evacuation lumen) clinical safety and tolerability study was performed at karolinska university hospital during 20128. the study showed that bip ett is safe, well tolerable and performs well in clinical settings. the present study of bip ett with evacuation lumen is randomized, prospective, controlled and blinded. all adult icu patients hospitalized in the icus from two tertiary hospitals (i.e.: centre hospitalier universitaire sart tilman liège , centre hospitalier chrétien de liège) and considered to be ventilated for more than 24 hours will be eligible to participate in the study. 300 patients in total will be used to determine baselines levels (150 in each group). the study tubes will be available not only in the icus but also in the emergency department, including the emergency vehicles, and in every hospital wards. the study tubes will not be available in the operating rooms except in the post anesthesia care units (pacu) and recovery rooms.

Eligibility criteria:
inclusion criteria: * intubation with a study tube and a presumed duration of ventilation for more than 24h, * age \> 18 y, * signed informed consent exclusion criteria: * tracheostomized patient * life expectancy less than 48h, * previous participation in the study * pregnant women.
angiotensin converting enzyme inhibitors in treatment of covid 19

Conditions: COVID

Summary: aceis as treatment for covid19

aceis as suggested treatment for covid19

Eligibility criteria:
inclusion criteria: * patients infected with covid 19 exclusion criteria: * allergy or contraindications to the drug
evaluation of the efficacy and safety of blu-5937 in adults with refractory chronic cough

Conditions: Refractory Chronic Cough

Summary: this is a randomized, double-blind, placebo-controlled, parallel-arm, phase 2b adaptive dose-finding study of blu-5937 in participants with refractory chronic cough (rcc).

the primary objective of this study is to determine the therapeutic dose of blu-5937 in patients with refractory chronic cough by assessing the change from baseline to week 4 in the 24-hour cough frequency with blu-5937 relative to placebo.

Eligibility criteria:
inclusion criteria: * capable of giving signed informed consent * refractory chronic cough (including unexplained chronic cough) for at least one year * women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose exclusion criteria: * current smoker/vaper (all forms of smoking and inhaled substances, including , cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history * diagnosis of chronic obstructive pulmonary disease (copd), bronchiectasis, idiopathic pulmonary fibrosis or uncontrolled asthma * respiratory tract infection within 4 weeks before screening * laboratory confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection at screening * history of malignancy in the last 5 years * history of alcohol or drug abuse within the last 3 years * has a positive serologic test for human immunodeficiency virus (hiv), hepatitis b virus surface antigen, or hepatitis c virus. * previous participation in a blu-5937 trial

Keywords: blu-5937 refractory chronic cough p2x3 receptor antagonist
a phase iii study of the safety and efficacy of entecavir in pediatric patients with chronic hepatitis b virus infection

Conditions: Chronic Hepatitis B Virus, Pediatric

Summary: the purpose of this study was to evaluate the safety and efficacy of entecavir in pediatric patients with chronic hepatitis b virus infection


Eligibility criteria:
key inclusion criteria * males and females, aged 2 to \<18 years * hepatitis b surface antigen-positive * detectable hepatitis b e (hbe) antigen, and no detectable anti-hbe antibodies * alanine aminotransferase (alt) 1.5 to \<10 times the upper limit of normal at screening and within 8 to 24 weeks prior to screening * evidence of the presence of hepatitis b virus dna at least 4 weeks before screening and \>100,000 copies/ml at screening key exclusion criteria * any prior therapy with entecavir * at least 12 weeks of prior therapy with any nucleoside or nucleotide antiviral agent * therapy with interferon alpha, thymosin alpha, or nucleototide antiviral agents within 24 weeks of screening * coinfection with hiv, hepatitis c virus, or hepatitis d virus * decompensated liver disease * liver transplant recipients * other forms of acute and chronic conditions which may cause increased alt levels * children who were breastfed while their mothers received lamivudine or whose mothers received lamivudine during pregnancy
a study to compare the efficacy and safety of idecabtagene vicleucel with lenalidomide maintenance therapy versus lenalidomide maintenance therapy alone in adult participants with newly diagnosed multiple myeloma who have suboptimal response after autologous stem cell transplantation

Conditions: Multiple Myeloma

Summary: the purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (len) maintenance to that of len maintenance alone in adult participants with newly diagnosed multiple myeloma (ndmm) who have achieved a suboptimal response post autologous stem cell transplantation (asct).


Eligibility criteria:
inclusion criteria * participants aged ≥18 with newly diagnosed multiple myeloma (ndmm) who has received induction therapy followed by high-dose chemotherapy and autologous stem cell transplantation (asct), without subsequent consolidation or maintenance. exception: participant received ≤ 7 days of lenalidomide (len) maintenance therapy and the investigator documents that there is no impact to the overall benefit/risk assessment due to the temporary interruption of len. * participant must have received 4 to 6 cycles of induction therapy, which must contain at a minimum an immunomodulatory drugs (imid) and a proteasome inhibitor (pi) (with or without anti-cd38 monoclonal antibody) and must have had a single asct 80 to 120 days prior to consent. note: participant must not have confirmed progression since commencing induction. * participant must have documented response of pr or vgpr at time of consent. * participant must have eastern cooperative oncology group (ecog) performance status ≤ 1 (participants with ecog 2 due to pain because of underlying myeloma-associated bone lesions are eligible per investigator's discretion). * participant must have recovered to ≤ grade 1 for any nonhematologic toxicities due to prior treatments, excluding alopecia and grade 2 neuropathy. exclusion criteria * participant with known central nervous system involvement with myeloma. * participant has non-secretory mm. * participant has systemic and uncontrolled fungal, bacterial, viral, or other infection. * participant has history of primary immunodeficiency. * participant has previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or b-cell maturation antigen targeted therapy. * other protocol-defined inclusion/exclusion criteria apply.

Keywords: car-t
observational study to investigate resistant hypertension prevalence in korean general hospitals

Conditions: Hypertension

Summary: study objectives the study is to identify prevalence, demography and clinical characteristics of patients with resistant hypertension among hypertensive patients who have been treated in general hospitals in korea from jan 2012 to jun 2012. * diagnosis of resistant hypertension: in case of clinic blood pressure exceeding the boundary of systolic blood pressure at 140mmhg and diastolic blood pressure at 90mmhg (hereinafter refer to as 140/90mmhg) (130/80mmhg for patients with diabetes mellitus or chronic renal disease) despite triple antihypertensive therapy at optimal dose may be diagnosed as resistant hypertension. antihypertensive medications used include diuretics. resistant hypertension may also be diagnosed when clinic blood pressure has reached the target value but quadruple or more of antihypertensives are used. * diagnosis of controlled hypertension: patients whose clinic blood pressure equals to 140/90mmhg (130/80mmhg for patients with diabetes mellitus or chronic renal disease) or less with the administration of antihypertensives at optimal dose may be diagnosed as controlled hypertension.

primary objective: prevalence in patients with resistant hypertension among hypertensive patients who have been treated in korean general hospitals secondary objectives: analysis of correlation in patients with resistant hypertension and patients with controlled hypertension who received triple antihypertensive therapy in terms of demography, clinical characteristics and other factors 1. demographic data (age, sex, and body mass index) 2. clinical characteristics * vital signs * lifestyles (history of drinking, smoking, and exercise) * family history (hypertension, diabetes mellitus, dyslipidemia, cardiovascular disease, renal/adrenal disease, cerebrovascular disease, and respiratory disease) * concurrent diseases (diabetes mellitus, dyslipidemia, cardiovascular disease, renal/adrenal disease, cerebrovascular disease, respiratory disease, and others) * history of antihypertensive therapy (past and present) * medication compliance of antihypertensives * concomitant medications

Eligibility criteria:
inclusion criteria: 1. patients diagnosed of hypertension and in 20 years of age or older at the time of participating the study 2. patients visiting the medical institution during the period of 01 2012 \~ 06 2012 and who have received triple or more of antihypertensive therapy including diuretics (all different classes one another) at the time of the investigation. 3. patients who signed the informed consent form for data use before undergoing the study procedures. 4. patients who have capability and are willing to understand and fill in the questionnaire used in this study or who have a representative to fill in the questionnaire in case of lacking the capability. exclusion criteria: 1. patients who fail to meet the inclusion criteria.
validation study of the velacur system in comparison to mre & mri-pdff in patients with (suspected) liver disease

Conditions: Non-alcoholic Fatty Liver Disease (NAFLD)

Summary: the goal of this open-label, non-randomized, prospective study is to compare velacur and mre in all sexes, 18-80 years old with non-alcoholic fatty liver disease (nafld). the main aims is to: * validate the use of velacur and elastography cut offs in a patient cohort with all types of chronic liver disease, against mre results for fibrosis staging. * validate the use of velacur and attenuation cut offs in a patient cohort with all types of chronic liver disease, against mri-pdff results for steatosis staging. participants will study participants will attend 1 study visit, in which measurement of liver stiffness with velacur and fibroscan, will be performed by a certified technician. as part of visit 1, patients will also complete an mri exam which will include both mre and mri-pdff measurements (mri imaging can take place within 28 days of the velacur scan).

this will be a prospective, open label, validation study of the velacur system in comparison to mre and mri-pdff in patients with liver disease or suspected liver disease. approximately 100 subjects may be enrolled in this study. participants should span all levels of fibrosis and steatosis. the study is comprised of: screening period (up to 8 days) and visit 1. there are no safety follow-up visits in this study. the primary objective of the study is to compare the results of velacur against mre and mri-pdff results for liver stiffness and steatosis. as part of prior studies, using mre as the gold standard, clinical cut-off for velacur have been developed. the primary objective of this study is to validate these cut-offs to see if velacur can correctly classify patients. secondary objectives include correlating the stiffness and attenuation results of velacur with other clinical measures of fibrosis and steatosis such as fib-4, and correlations with other clinical measurements collected through clinical care or clinical trials, such as enhance liver fibrosis (elf) test, fibroscan, mri, or ultrasound based shear wave elastography (swe) as they are available.

Eligibility criteria:
inclusion criteria: patients with evidence of nafld or other chronic liver disease such as one of the following: biopsy proven chronic liver disease or evidence of hepatic steatosis or chronic liver disease on non-invasive assessment by one or more of the following criteria: * abdominal ultrasound within 12 months * mri-pdff (greater than 12%) within 12 months * fibroscan cap score \> 230 db/m within 12 months or at least 2 criteria for metabolic syndrome and increased stiffness on fibroscan (\>8kpa) within 12 months exclusion criteria: * bmi greater than 40 kg/m2 (or unable to fit into mri bore) * subject with current, significant alcohol consumption or history of significant alcohol consumption * subjects with evidence of decompensated liver disease

Keywords: nash nafl